Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Genome Announc ; 3(2)2015 Apr 09.
Article in English | MEDLINE | ID: mdl-25858844

ABSTRACT

Here, we report the completed genome sequence of a carbapenem-resistant extraintestinal pathogenic Escherichia coli sequence type 131 (ST131) isolate, MNCRE44. The isolate was obtained in 2012 in Minnesota, USA, from a sputum sample from a hospitalized patient with multiple comorbidities, and it belongs to the H30R sublineage.

2.
Foodborne Pathog Dis ; 8(4): 555-60, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21186994

ABSTRACT

Clinical laboratory practices affect patient care and disease surveillance. It is recommended that laboratories routinely use both culture for Escherichia coli O157 and a method that detects Shiga toxins (Stx) to identify all Stx-producing E. coli (STEC) and that labs send broths or isolates to a public health laboratory. In 2007, we surveyed laboratories serving Foodborne Diseases Active Surveillance Network sites that performed on-site enteric disease diagnostic testing to determine their culture and nonculture-based testing practices for STEC identification. Our goals were to measure changes over time in laboratory practices and to compare reported practices with published recommendations. Overall, 89% of laboratories used only culture-based methods, 7% used only Stx enzyme immunoassay (EIA), and 4% used both Stx EIA and culture-based methods. Only 2% of laboratories reported simultaneous culture for O157 STEC and use of Stx EIA. The proportion that ever used Stx EIA increased from 6% in 2003 to 11% in 2007. The proportion that routinely tested all specimens with at least one method was 66% in 2003 versus 71% in 2007. Reference laboratories were less likely than others to test all specimens routinely by one or more of these methods (48% vs. 73%, p=0.03). As of 2007, most laboratories complied with recommendations for O157 STEC testing by culture but not with recommendations for detection of non-O157 STEC. The proportion of laboratories that culture stools for O157 STEC has changed little since 2003, whereas testing for Stx has increased.


Subject(s)
Bacterial Typing Techniques , Enteritis/microbiology , Escherichia coli Infections/microbiology , Sentinel Surveillance , Shiga-Toxigenic Escherichia coli/classification , Shiga-Toxigenic Escherichia coli/isolation & purification , Bacterial Typing Techniques/trends , Centers for Disease Control and Prevention, U.S. , Escherichia coli Infections/diagnosis , Escherichia coli Infections/epidemiology , Escherichia coli O157/classification , Escherichia coli O157/isolation & purification , Escherichia coli O157/metabolism , Feces/microbiology , Guideline Adherence , Humans , Shiga Toxin/metabolism , Shiga-Toxigenic Escherichia coli/metabolism , Surveys and Questionnaires , United States/epidemiology
3.
Public Health Rep ; 125 Suppl 2: 4-17, 2010.
Article in English | MEDLINE | ID: mdl-20521374

ABSTRACT

This article describes the development since 2000 of the State Public Health Laboratory System in the United States. These state systems collectively are related to several other recent public health laboratory (PHL) initiatives. The first is the Core Functions and Capabilities of State Public Health Laboratories, a white paper that defined the basic responsibilities of the state PHL. Another is the Centers for Disease Control and Prevention National Laboratory System (NLS) initiative, the goal of which is to promote public-private collaboration to assure quality laboratory services and public health surveillance. To enhance the realization of the NLS, the Association of Public Health Laboratories (APHL) launched in 2004 a State Public Health Laboratory System Improvement Program. In the same year, APHL developed a Comprehensive Laboratory Services Survey, a tool to measure improvement through the decade to assure that essential PHL services are provided.


Subject(s)
Interinstitutional Relations , Laboratories/organization & administration , Population Surveillance , Public Health Administration , United States Public Health Service/organization & administration , Communicable Disease Control , Disaster Planning , Humans , Laboratories/standards , Local Government , United States , United States Public Health Service/standards
4.
Antimicrob Agents Chemother ; 47(7): 2161-8, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12821463

ABSTRACT

Fluoroquinolone use in poultry production may select for resistant Escherichia coli that can be transmitted to humans. To define the prevalence and virulence potential of poultry-associated, quinolone-resistant E. coli in the United States, 169 retail chicken products from the Minneapolis-St. Paul area (1999 to 2000) were screened for nalidixic acid (Nal)-resistant E. coli. Sixty-two (37%) products yielded Nal-resistant E. coli. From 55 products that yielded both Nal-resistant and susceptible E. coli, two isolates (one resistant, one susceptible) per sample were further characterized. Twenty-three (21%) of the 110 E. coli isolates (13 resistant, 10 susceptible) satisfied criteria for extraintestinal pathogenic E. coli (ExPEC), i.e., exhibited >or=2 of pap (P fimbriae), sfa/foc (S/F1C fimbriae), afa/dra (Dr binding adhesins), iutA (aerobactin receptor), and kpsMT II (group 2 capsule synthesis). Compared with other isolates, ExPEC isolates more often derived from virulence-associated E. coli phylogenetic groups B2 or D (74% versus 32%; P < 0.001) and exhibited more ExPEC-associated virulence markers (median, 10.0 versus 4.0; P < 0.001). In contrast, the Nal-resistant and -susceptible populations were indistinguishable according to all characteristics analyzed, including pulsed-field gel electrophoresis profiles. These findings indicate that Nal-resistant E. coli is prevalent in retail poultry products and that a substantial minority of such strains represent potential human pathogens. The similarity of the Nal-resistant and -susceptible populations suggests that they derive from the same source population, presumably the avian fecal flora, with Nal resistance emerging by spontaneous mutation as a result of fluoroquinolone exposure.


Subject(s)
Anti-Infective Agents/pharmacology , Escherichia coli Infections/veterinary , Escherichia coli/isolation & purification , Nalidixic Acid/pharmacology , Poultry Diseases/microbiology , Animals , Chickens , Cluster Analysis , Drug Resistance, Bacterial , Escherichia coli/drug effects , Escherichia coli/genetics , Escherichia coli/pathogenicity , Escherichia coli Infections/drug therapy , Escherichia coli Infections/microbiology , Feces/microbiology , Intestines/microbiology , Microbial Sensitivity Tests , Mutation , O Antigens/genetics , Phenotype , Phylogeny , Poultry Diseases/drug therapy , Poultry Products/microbiology , Random Amplified Polymorphic DNA Technique , Virulence , Virulence Factors/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...